# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced it recently received 510(k) clea...
Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:GMED) with a Hold and raises the price target from...
BTIG analyst Ryan Zimmerman maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $72 to $75.
Morgan Stanley analyst Drew Ranieri maintains Globus Medical (NYSE:GMED) with a Equal-Weight and raises the price target fro...
U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cu...
BTIG analyst Ryan Zimmerman maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $63 to $72.